23 results about "Regulatory Pathway" patented technology

The invention relates to the technical field of cotton alkali-resistant gene mining, and particularly discloses a method for jointly screening key genes responding to upland cotton alkali stress based on transcriptome and metabolome, which comprises the following steps: carrying out alkali stress treatment on upland cotton to obtain tissue samples at different time points; performing transcriptome sequencing and metabolome sequencing on the tissue sample to respectively obtain gene expression data and metabolite data; performing difference analysis on the gene expression data and the metabolite data to obtain DEGs and DAMs; carrying out conjoint analysis on the DEGs and the DAMs, and screening to obtain a key gene and a regulatory pathway which respond to alkali stress; analyzing the key gene and the regulatory pathway through a gene expression verification technology to obtain an expression mode; according to the invention, 15 candidate genes related to the alkali resistance of the upland cotton are screened through WGCNA, a theoretical basis is provided for deeply knowing the molecular mechanism of the alkali resistance of the upland cotton, and a new gene resource is provided for subsequent research.

The application provides application of a TT2-SCT1 / SCT2-WR2 regulation channel in plant heat stress tolerance. The application first discloses a new signal channel involved in plant heat tolerance: a TT2-SCT1 / SCT2-WR2 signal channel; wherein, TT2 is a negative regulation factor for regulating the heat tolerance of plants or protecting (maintaining) the yield of plants in Gramineae under high temperature, SCT1 / SCT2 are also negative regulation factors for regulating the heat tolerance of plants or protecting (maintaining) the yield of plants in Gramineae under high temperature, and WR2 is a positive regulation factor for playing a role, which is beneficial to maintaining the homeostasis in plants. The application has important theoretical significance for genetic improvement of plant traits.

This application relates to the field of tumor metabolic biomarker detection technology, and discloses a method for detecting glucose metabolism biomarkers in esophageal cancer based on VAV2-related molecular characteristics. The method includes: performing immunohistochemical staining on esophageal cancer tissue samples to obtain VAV2, EIF3F, MTA1, and HIF-1α protein expression sections; scoring the immunoreaction of each section; calculating a comprehensive glucose metabolism phenotype score based on the molecular hierarchy of the VAV2-EIF3F-MTA1 / HIF-1α glucose metabolism regulatory pathway; and classifying the samples into high-glycolytic, moderate-glycolytic, and low-glycolytic types according to the comprehensive score. This application improves the accuracy and stability of glucose metabolism phenotype discrimination in esophageal cancer.

The invention belongs to the technical field of plant genetic engineering and molecular breeding, and particularly relates to a new function and application of a transcription factor gene OsMYB87 derived from rice, an OsMYB87 function deletion mutant created through a gene editing technology and application of the OsMYB87 function deletion mutant in increasing the rice grain length and grain weight. The OsMYB87 gene found in the invention shows a key differentiated characteristic: preliminary phenotypic observation shows that the phenomenon that chalkiness of endosperm is remarkably aggravated inevitably due to OsMYB73 knockout is not observed while the function deficiency of the OsMYB87 gene brings a remarkable yield increasing effect (grain length and grain weight increase). The OsMYB87 is strongly prompted to be possibly located on a different regulatory pathway, and as a breeding target, the OsMYB87 provides greater possibility and a better potential choice for maintaining the appearance quality of rice commodities while realizing yield increase, so that the OsMYB87 has higher application value.

This invention discloses a method and application for regulating fatty liver syndrome based on osteocalcin-adiponectin receptor, relating to the field of livestock and poultry metabolic disease prevention and control technology. The method includes the following steps: clarifying the clinical symptoms and pathological changes of fatty liver syndrome in laying hens; constructing a complementary validation system for fatty liver syndrome models, including an in vivo FLS model in laying hens and an in vitro LMH model of chicken liver cancer cells; using osteocalcin OCN and the adiponectin receptor agonist AdipoRon to target and intervene in the in vivo FLS model and the in vitro LMH model of chicken liver cancer cells, and conducting multi-dimensional detection and evaluation of the regulatory effect; by specifically silencing the expression of AdipoR1 or AdipoR2, comparing changes in lipid deposition and signaling pathways in cells treated with osteocalcin, and identifying the functional hierarchy of AdipoR1 and AdipoR2 in the osteocalcin regulatory pathway; this invention achieves precise prevention and treatment of fatty liver syndrome in laying hens through complementary validation models, targeted intervention with osteocalcin and AdipoRon, and identification of adiponectin receptor function.

The invention discloses an application of a fat factor C1q / TNF (Tumor Necrosis Factor) associated protein 9 (CTRP-9) in enhancing T cell immunotherapy, and relates to a new application of the fat factor C1q / TNF associated protein 9 (CTRP-9) in regulating T cell functions, and the CTRP-9 is an immune regulation molecule secreted by fat tissues. According to the present invention, the CTRP-9 is exogenously supplemented, such that the effect intensity of the T cells in the anti-tumor immunoreaction can be effectively enhanced, and the activation and the proliferation of the T cells can be promoted; meanwhile, the CTRP-9 can also be used as a CAR-T cell enhancer, so that the immunotherapy effect is improved. The method can be applied to an immunotherapy system based on T cells, and provides a new regulation way and target for improving the T cell immunotherapy effect.

The invention belongs to the technical field of genes, discloses a method for detecting and mining associated genes and regulatory pathways by using double-layer optimization, solves the black box problem in a machine learning prediction process and provides biological mechanism explanation. The previous research mostly utilizes multi-omics data to predict phenotypes, but a machine learning mode is difficult to really evaluate the action size and action approach of genes, and lacks interpretability at the same time. According to the RADAR, a parameter is given to each omics of each gene for double-layer optimization solution, phenotypes can be explained to the maximum extent, and meanwhile the action degree of each omics can be evaluated. In addition, RADAR can process input data of any number of omics, and a program can automatically identify the number of the omics and calculate the effect size of each omics. RADAR can accept omics input of different gene numbers, and the actual data condition is better met.

The invention discloses application of HLA-DP in neuromyelitis optica diagnosis and recurrence risk assessment, HLA-DPB1 gene polymorphism affects NMOSD susceptibility and disease state, existence of HLA-DPB1 * 0501 allelotype changes expression level of HLA-DPB1 molecules on APC of peripheral blood of a patient, abnormal activation of T cells is caused, blood brain / retina barrier is damaged, and the neuromyelitis optica is diagnosed. Humoral immunity and cellular immunity in the central nervous system are abnormally activated, resulting in the generation of NMOSD focuses and the onset of NMOSD. According to the application disclosed by the invention, an NMOSD mouse model is constructed by using an HLA-DPB1 transgenic mouse to verify that the HLA-DPB1 * 05: 01 allelotype can induce generation of an NMOSD focus and explore a downstream regulatory pathway by changing the expression level of HLA-DP on the surface of APC in peripheral blood, so that a thought is provided for exploring the pathogenesis of the NMOSD and searching a new therapeutic target.

The invention provides a composition based on elderberry and application of the composition to elimination of pulmonary nodules. The composition is prepared from an elderberry extract, a radix salviae miltiorrhizae extract, a sophora flower bud extract, beta-glucan, menthol and curcumin. The composition provided by the invention carries multiple components, multiple targets and multiple regulatory pathways to interact in a preparation. On one hand, the composition can inhibit generation and release of inflammatory factors by regulating oxidative stress, and on the other hand, the composition can prevent and eliminate pulmonary nodules by blocking generation of angiotensin II, inhibiting vascular hyperplasia and inflammatory response and regulating immunosuppression inflammation. The oral preparation described in the invention can be a drug loading system such as a capsule, a tablet, a granule, a suspension or an emulsion.

The invention belongs to the technical field of biological medicine, and particularly relates to application of pseudo-ginseng carbon quantum dots in preparation of a medicine for treating renal ischemia-reperfusion injury, the carbon quantum dots are synthesized by taking pseudo-ginseng as a raw material through a hydrothermal method, and the pseudo-ginseng carbon quantum dots have the antioxidant enzyme activity property, can effectively relieve cell oxidative stress and inhibit secretion of proinflammatory cytokines, and can be used for preparing a medicine for treating renal ischemia-reperfusion injury. The pseudo-ginseng carbon quantum dots specifically gather in the damaged kidney, so that the renal ischemia reperfusion injury of the mouse is obviously relieved; the pseudo-ginseng carbon quantum dots can relieve kidney injury through the following ways: reducing abundance of escherichia coli-shigella, reducing the level of indol sulfate in the kidney, regulating tryptophan-indole metabolism, regulating an AHR-Raf-ERK signal channel, down-regulating the levels of TNF-alpha and malonaldehyde, and regulating the level of glutathione. A catalytic mechanism and a multi-omics regulatory pathway of the pseudo-ginseng carbon quantum dots in renal ischemia reperfusion injury are disclosed, and experimental evidence is provided for'intestinal tract-kidney axis' in kidney disease treatment.

The invention discloses a Crassostrea hongkongensis VgR gene and an shRNA-VgR sequence and application thereof, a VgR gene segment is obtained by screening and cloning from a Crassostrea hongkongensis transcriptome, shRNA is designed and synthesized according to the Crassostrea hongkongensis VgR gene sequence, and the shRNA is named as shRNA-VgR. The method comprises the following steps: introducing the VgR gene into Crassostrea hongkongensis by injecting adductor muscle to interfere and inhibit the expression of the VgR gene in the Crassostrea hongkongensis, detecting the expression and location distribution change of the interfered VgR gene, the activity change of related signal channel key genes and key enzymes regulated by the VgR gene, the morphological structure change of related tissues, the cell apoptosis condition and the like, and identifying the Crassostrea hongkongensis in the Crassostrea hongkongensis. And systematically analyzing the effect of the VgR gene and the regulatory pathway thereof in the physiological process of the crassostrea hongkongensis and the regulatory mechanism thereof. The injection dosage is small, the cost can be reduced, and regulation and control of VgR-guided related signal channels on physiological functions of crassostrea hongkongensis can be effectively influenced.

The invention belongs to the field of biological medicine, and particularly relates to a plumbagin isomer PLB-1 as well as a composition and application of the plumbagin isomer PLB-1. The plumbagin isomer PLB-1 and the composition are deeply researched through molecular biology, transcriptome sequencing and animal experiment related experimental means, the specific regulation and control mechanism of the plumbagin isomer to an NQO1 / HO-1 pathway and the specific synergistic effect of HAS-NPs (at) PLB-1 (at) PD-L1 to plumbagin, and the specific regulation and control mechanism of the plumbagin isomer PLB-1 (at) PD-L1 and the specific regulation and control mechanism of the a leading bioinformatics method is combined, a new regulatory pathway of the PLB-1 is explored, and the action effect of the PLB-1 is further improved by taking an albumin nano material as a drug carrier. A new treatment mode is provided for the lung cancer, meanwhile, a new way is provided for application of PLB-1, and breakthrough of fundamental research on treatment of the lung cancer by PLB is achieved.

The invention discloses a rice basic vegetative growth period regulatory factor OsMADS64 gene as well as an encoding protein and application thereof, and belongs to the technical field of gene engineering. The amino acid sequence of the protein coded by the gene OsMADS64 is as shown in SEQ ID NO. 2, and the nucleotide sequence is as shown in SEQ ID NO. 1. According to the invention, the OsMADS64 is located in a cell nucleus and cytoplasm; a spatio-temporal expression analysis result shows that the OsMADS64 gene is expressed in roots, stems, leaf sheaths and leaves in different periods, but the expression quantity in the roots is the highest; the osmads64 mutant obtained by a gene editing technology shows a heading delay phenotype under long-day and short-day conditions, which indicates that the regulation of the OsMADS64 on the heading period of the rice does not completely depend on a photoperiod. The invention enriches and perfects the rice heading stage regulation pathway to a certain extent, provides an important theoretical basis for molecular breeding for modifying the ripe stage of rice, and has a wide application prospect.

The invention relates to the technical field of traditional Chinese medicine network pharmacology and virtual screening analysis, in particular to a method for analyzing active ingredients and specific signal pathways of coptis flower stalk extract for improving insulin resistance based on virtual screening. According to the method, the screening model suitable for the GSK3B target inhibitor is constructed, and the inventor further optimizes the model, so that the accuracy of screening the GSK3B target inhibitor by the model is greatly improved. The method provides a new thought for explaining a molecular mechanism of the coptis chinensis flower stalk for treating insulin resistance, and lays a foundation for further research and development of an innovative preparation of the coptis chinensis flower stalk extract for treating insulin resistance.

The invention relates to the field of biological information, in particular to a gene abnormality regulation and control detection method based on regulation and control pathway disturbance analysis, and the method comprises the following steps: collecting biological samples and pathway structure data; obtaining a weighted optimized pathway disturbance score through the gene dynamic behavior and the pathway context information; obtaining a gene dynamic influence factor through the difference expression significance and the consistency between the samples; obtaining a context association optimization factor of the pathway specificity through a pathway topological structure and expression coordination; optimizing a GSVA path disturbance score through the comprehensive contribution weight; and the abnormal regulatory pathway is identified based on the optimized score, so that the sensitivity and accuracy of the gene set variation analysis method in complex disease pathway disturbance identification are improved.

The present invention belongs to the field of biomedicine or health care products, and specifically discloses a method for culturing stem cell exosomes for anti-aging and its application. The method significantly increases the exosome yield to 2.1×10 11 particles / mL; TGF-β1, IFN-γ, and NMN were added in stages to synergistically activate immune regulatory pathways, increasing TGF-β1 levels to 8.5 ng / μg. The exosomes and active ingredients (vitamin C ethyl ether, Q10, and astaxanthin) were co-encapsulated in liposomes (HSPC:cholesterol = 7:3). After oral administration, the gastric fluid stability reached 92.3%, and the intestinal absorption rate increased to 80%. Experiments showed that this composition increased the proportion of Tregs in the spleen of elderly mice by 35%, reduced IL-6 levels by 48%, and improved skin barrier function (TEWL decreased by 40%). Long-term toxicity studies confirmed its safety (no abnormalities in ALT). This invention represents a significant technological advancement and clinical application potential in the anti-aging field.

This invention discloses a natural selenium-enriched black soybean sprout endogenous synergistic extract, its preparation method, and its applications, belonging to the fields of food biotechnology and functional foods. Using high-selenium naturally enriched black soybeans as a single raw material, with no exogenous selenium added throughout the process, anthocyanins are enriched through light-protected germination. This is combined with enzymatic hydrolysis and membrane separation purification to construct a multi-component endogenous synergistic system. The extract is rich in highly converted organic selenium, small molecule peptides, anthocyanins, and endogenous phytase, exhibiting characteristics such as resistance to gastric acid, slow release into the intestine, and promotion of mineral absorption. Relying on the synergistic effects of multiple metabolic regulatory pathways, the product can achieve liver protection and detoxification, cell repair, antioxidant effects, and fat reduction. It effectively improves the shortcomings of traditional compound products, such as weak stability, low absorption rate, and large batch-to-batch variations. The production process is stable, with significant industrialization advantages, and it can be widely applied in the fields of functional foods, special dietary foods, and dietary supplements.

The invention discloses an application of Degrasynn (WP1130) as a PTBP1 degradation agent in preparation of DMD treatment drugs, and belongs to the technical field of biological medicines. According to the application, a B10-DMD-KO model mouse experiment proves that PTBP1 plays a key regulation role in DMD skeletal muscle regeneration for the first time, and Degrasynn (WP1130) can effectively degrade PTBP1 protein and remarkably improve muscle aplastic disorder. Based on the discovery, the invention provides a pharmaceutical composition taking Degrasynn (WP1130) as an active component, a collaborative treatment scheme of Degrasynn (WP1130) and a PTBP1 gene silencing agent, and a matched PTBP1 expression detection kit. The action mechanism of the PTBP1 regulatory pathway in DMD treatment is disclosed in a breakthrough mode, and compared with a traditional therapy, the PTBP1 regulatory pathway has the remarkable advantages of being accurate in targeting and low in toxic and side effect.

A method for treating myopia is provided. Specifically, the method includes administering a mitogen-activated protein kinase (MAPK) signaling pathway inhibitor to a subject in need thereof. The inhibitor targets one or more kinases selected from MEK1, MEK2, ERK1, and ERK2, thereby modulating MAPK pathway activity to control ocular growth and progression of myopia.

This invention discloses a polypeptide targeting mitochondrial ribonuclease P and its application in the preparation of antitumor drugs. Based on the principle of the inhibition of mtRNA P by the endogenous natural peptide AC027045.3, this invention designs a novel polypeptide based on the amino acid sequence of the binding functional domain of AC027045.3. This polypeptide is designed based on the natural polypeptide sequence and functions by mimicking the endogenous physiological regulatory pathway. Compared to the natural peptide, this novel polypeptide has a shorter sequence, which is beneficial for chemical synthesis. Given the high energy dependence of actively proliferating tumor cells, this invention uses mtRNA P as a novel target for tumor therapy, designing a targeting peptide to inhibit the mitochondrial oxidative phosphorylation process and exert an anti-cancer effect.

This invention discloses an exosome miR-105-5p and its application in the preparation of drugs for treating spinal cord injury, belonging to the field of molecular biology. The nucleotide sequence of the exosome miR-105-5p is shown in SEQ ID NO: 1. Through the construction of a rat model of spinal cord injury, it was found that the levels of inflammatory factors such as IL-6 in the spinal cord tissue of the model group were significantly increased. Bioinformatics results showed that miR-105-5p can regulate IL-6, and dual-luciferase reporter gene assays confirmed a direct regulatory relationship between the two. In vitro experiments on cultured nerve cells and animal experiments showed that miR-105-5p in exosomes downregulated IL-6 expression. This invention discovers a novel exosome-mediated non-coding RNA-related regulatory pathway in rats with spinal cord injury, providing an experimental basis and research ideas for future drug development, disease diagnosis, and prognosis prediction.

The present invention relates to the field of animal disease models. A method for constructing and using a pathological myopia animal model provided by the present invention includes: inducing with a negative lens in combination with intervention with an mTOR activator to obtain a pathological myopia animal model; the present invention has found through research that when an mTOR activator based on the key regulatory pathway of myopic axial elongation is combined with negative lens induction to intervene in animals, it can efficiently induce animals to develop pathological myopia. All animals showed significant tigroid fundus (pathological myopia in stage M1), and 25% of guinea pigs showed diffuse and patchy choroidal atrophy around the optic disc, which is characteristic of pathological myopia (pathological myopia in stages M2 - M3). This kind of pathological myopia animal model is easy to induce and highly similar to the fundus changes of human pathological myopia, which can fill the gap in pathological myopia animal models and can be used as a new animal model for exploring the causes and mechanisms of the occurrence and development of pathological myopia.

The invention belongs to the field of biological medicine, and particularly relates to application of NFKBIZ and TRIM16 in hepatocellular carcinoma. The invention relates to an application of a TRIM16 / NFKBIZ / NF-kappa B axis in preparation of a hepatocellular carcinoma diagnosis product or a hepatocellular carcinoma treatment drug. NFKBIZ regulates and controls conduction of a downstream NF-kappa B signal through interaction with TRIM16. The application finds that the prognosis of an HCC (hepatocellular carcinoma) patient with low NFKBIZ expression is poor, and NFKBIZ regulates and controls the proliferation and metastasis of HCC cells by regulating an NF [kappa] B pathway. The application also finds that the inhibition effect of the NFKBIZ on the HCC cells is weakened by the TRIM16 by increasing the ubiquitination of the NFKBIZ. The overexpression of the NFKBIZ enhances the apoptosis rate of the HCC cells, and under the treatment of sorafenib, the TRIM16 relieves the effect by promoting the degradation of the NFKBIZ. These findings prompt the potential effect of NFKBIZ as a new target for HCC treatment and prognosis, and it as a key target for protecting the sensitivity of HCC to sorafenib.